NDC 0074-2306

Rinvoq

Upadacitinib

Rinvoq is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is Upadacitinib.

• Product ID: 0074-2306_0c1f0eb7-336d-4a9a-a348-e7c5212e3f73
• NDC: 0074-2306
• Product Type: Human Prescription Drug
• Proprietary Name: Rinvoq
• Generic Name: Upadacitinib
• Dosage Form: Tablet, Extended Release
• Route of Administration: ORAL
• Marketing Start Date: 2019-08-16
• Marketing Category: NDA / NDA
• Application Number: NDA211675
• Labeler Name: AbbVie Inc.
• Substance Name: UPADACITINIB
• Active Ingredient Strength: 15 mg/1
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 0074-2306-30

30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-30)

• Marketing Start Date: 2019-08-16
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0074-2306-70 [00074230670]

Rinvoq TABLET, EXTENDED RELEASE

• Marketing Category: NDA
• Application Number: NDA211675
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2019-08-16

NDC 0074-2306-30 [00074230630]

Rinvoq TABLET, EXTENDED RELEASE

• Marketing Category: NDA
• Application Number: NDA211675
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2019-08-16

Drug Details

Active Ingredients

Ingredient	Strength
UPADACITINIB	15 mg/1

OpenFDA Data

• SPL SET ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095
• Manufacturer:
  • AbbVie Inc.
• UNII:
  • 4RA0KN46E0
• RxNorm Concept Unique ID - RxCUI:
  • 2196900
  • 2196894

NDC Crossover Matching brand name "Rinvoq" or generic name "Upadacitinib"

NDC	Brand Name	Generic Name
0074-1043	Rinvoq	Upadacitinib
0074-2306	Rinvoq	Upadacitinib
0074-2310	Rinvoq	Upadacitinib